Endocrine Abstracts

BRAFV600E mutation is considered useful in recognizing thyroid cancer aggressiveness or poor prognosis particularly in certain variants of papillary thyroid cancinoma (PTC). A recent meta-analysis identified 12 cancer-versus-non cancer gene candidate as markers of thyroid cancer; among these TIMP-1 (tissue inhibitors of metalloproteinases) was found consistently up-regulated. Our aim was to evaluate BRAFV600E mutation and TIMP-1 expression in 14 PTC class...

A strong evidence suggests the role of BRAFV600E mutation in determining the aggressiveness of thyroid cancer. To detect how the association of BRAF mutation could influence the aggressiveness of particular subtypes of thyroid tumors, we analysed a possible correlation between BRAFV600E and metalloproteinase (MMPs) activity, as its enhanced production could be an important determinant of tumor invasion. For this purpose, we investigated the activity and t...